Relmada Therapeutics Inc. (NASDAQ: RLMD)
$3.79
-0.0500 ( -1.30% ) 63.9K
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Market Data
Open
$3.79
Previous close
$3.84
Volume
63.9K
Market cap
$113.76M
Day range
$3.76 - $3.89
52 week range
$2.42 - $7.22
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Mar 19, 2024 |
10-k | Annual reports | 59 | Mar 19, 2024 |
4 | Insider transactions | 1 | Jan 31, 2024 |
4 | Insider transactions | 1 | Jan 31, 2024 |
4 | Insider transactions | 1 | Jan 31, 2024 |
8-k | 8K-related | 12 | Jan 11, 2024 |
8-k | 8K-related | 14 | Jan 04, 2024 |
8-k | 8K-related | 12 | Jan 03, 2024 |
4 | Insider transactions | 1 | Dec 19, 2023 |
4 | Insider transactions | 1 | Dec 19, 2023 |